Phaseline

Companies › National Vaccine and Serum Institute, China

National Vaccine and Serum Institute, China: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Infectious disease; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha)
Recombinant HPV vaccine covering 11 HPV types
HPVPhase 3HPV InfectioNJun 2028
Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Recombinant human papillomavirus vaccine (HPV types 6, 11, 16, 18)
HPV6, HPV11, HPV16, HPV18Phase 3Human Papillomavirus (HPV) InfectionJul 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0526201011-valent recombinant human papillomavirus vaccine (Hansenula polymorpha)Phase 3HPV InfectioNInfectious diseaseJun 2028
NCT06632912Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)Phase 3Human Papillomavirus (HPV) InfectionInfectious diseaseJul 2032

Targets

HPV (1) HPV6 (1) HPV11 (1) HPV16 (1) HPV18 (1)

Companies with the same targets

Merck & Co. (MSD) Beijing Health Guard Biotechnology Shanghai Bovax Biotechnology

Companies built like this

Beijing Health Guard Biotechnology Shanghai Bovax Biotechnology ARJ Medical NPO Petrovax Xiamen Innovax Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.